Included in the formulation
Pharmacodynamics:Coagulation of proteins of microbial cells.
Antiseptic preparation, active against gram-positive and gram-negative microorganisms in vitro, has an antifungal effect. Lidocaine also has a local anesthetic and anti-edematous effect.
Lidocaine causes a blockade of initiation and carrying out of nerve impulses: a decrease in the permeability of cell membranes of neurons for Na ions+, probably by attachment to sodium channels, and an increase in permeability for K+, which reversibly stabilizes the cell membrane and depresses its depolarization, disrupts the propagation of the action potential and leads to a blockade of conductivity. For blockade of large nerve trunks, a higher concentration of the drug is required than for small peripheral nerves.
Antiviral effect (influenza A virus, respiratory syncytial virus, coronavirus of severe acute respiratory syndrome).
Pharmacokinetics:Amylmetacresol + Dichlorobenzyl alcohol - not studied. Lidocaine bIt is rapidly absorbed from the mucous membranes, especially from the mucous membrane of the airways; penetrates through blood-brain barrier, placental barrier and into breast milk (40% concentration in the mother plasma). The connection with plasma proteins is moderate or high (60-80% depending on the concentration). Biotransformation in the liver - 90-95%, with the participation of microsomal enzymes. Half-life dose-dependent and is in adults after an intravenous bolus injection of 1.5-2 hours (an average of 100 minutes), in newborns - 3.2 hours; with the infusion of lidocaine within 24-48 h half-life increases to 3 hours; when the liver functions, the half-life can increase in 2 times. Elimination - kidney 10% in unchanged form, but mainly in the form of metabolites; Renal excretion may be preceded by excretion of bile with subsequent reabsorption from the digestive tract. With chronic renal failure, cumulation of metabolites is possible; Acidification increases the excretion of lidocaine.
Indications:Symptomatic treatment of severe sore throat with infectious inflammationDiseases of the oral cavity and pharynx.
X.J00-J06.J02.9 Acute pharyngitis, unspecified
X.J30-J39.J35.0 Chronic tonsillitis
X.J00-J06.J03.9 Acute tonsillitis, unspecified
X.J30-J39.J37 Chronic laryngitis and laryngotracheitis
X.J00-J06.J04 Acute laryngitis and tracheitis
XVIII.R00-R09.R07.0 A sore throat
Contraindications: Hypersensitivity, children's age (up to 12 years). For a spray - an attack of bronchial asthma.
Carefully:Diabetes mellitus (1 tablet contains 2.6 mg of sugar). Pregnancy, lactation; for the spray - bronchial asthma.
Pregnancy and lactation:The category of FDA recommendations is not defined. Adequate and well-controlled studies on humans and animals have not been conducted.
There is no information on the penetration into breast milk. Application for pregnancy and lactation (breastfeeding) is possible according to the indications and only under the supervision of the doctor.
Dosing and Administration:Locally. Adults and children over 12 years old - resorb one tablet every 2-3 hours (no more than 8 tablets within 24 hours). The maximum daily dose is 8 tablets. Tablets should be resorbed in the mouth until completely dissolved.
Spray: adults and children over 12 years of age - irrigate the inflamed area by double pressing the head of the vial (1 dose); if necessary, repeat the procedure every 3 hours (no more than 6 doses within 24 hours).Duration of application - no more than 5 days.
Side effects:Allergic reactions, loss of sensitivity of the tongue (care must be taken when taking hot food and water); in some cases, the resorptive toxic effect of lidocaine is possible.
Overdose:It is unlikely that a possible overdose can lead to severe anesthesia of the upper digestive tract. Nausea, vomiting, diarrhea.
Treatment: symptomatic.
Interaction:Clinically significant interactions with other drugs have not been identified.
Special instructions:In case of accidental miss of one or more doses, the dose is not increased.